168 related articles for article (PubMed ID: 33952288)
1. An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy.
Gabriele D; Guarneri A; Bartoncini S; Munoz F; Tamponi M; Russo F; Stamatakos G; Guiot C; Regge D; Ricardi U
Radiat Oncol; 2021 May; 16(1):85. PubMed ID: 33952288
[TBL] [Abstract][Full Text] [Related]
2. Beyond D'Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier.
Gabriele D; Jereczek-Fossa BA; Krengli M; Garibaldi E; Tessa M; Moro G; Girelli G; Gabriele P;
Radiat Oncol; 2016 Feb; 11():23. PubMed ID: 26911291
[TBL] [Abstract][Full Text] [Related]
3. External validation of the Candiolo nomogram for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy: a retrospective cohort study.
Utsumi T; Suzuki H; Ishikawa H; Hiroshima Y; Wakatsuki M; Harada M; Ichikawa T; Akakura K; Tsuji H
Jpn J Clin Oncol; 2022 Aug; 52(8):950-953. PubMed ID: 35462397
[TBL] [Abstract][Full Text] [Related]
4. A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
Elshafei A; Kovac E; Dhar N; Levy D; Polascik T; Mouraviev V; Yu C; Jones JS
Prostate; 2015 Sep; 75(13):1447-53. PubMed ID: 26172607
[TBL] [Abstract][Full Text] [Related]
5. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.
Leyh-Bannurah SR; Dell'Oglio P; Tian Z; Schiffmann J; Shariat SF; Suardi N; Francesco M; Alberto B; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
World J Urol; 2017 Feb; 35(2):189-197. PubMed ID: 27289238
[TBL] [Abstract][Full Text] [Related]
6. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of the Kattan nomogram across prostate cancer risk-groups.
Korets R; Motamedinia P; Yeshchina O; Desai M; McKiernan JM
BJU Int; 2011 Jul; 108(1):56-60. PubMed ID: 21062396
[TBL] [Abstract][Full Text] [Related]
8. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
[TBL] [Abstract][Full Text] [Related]
9. Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.
Donovan MJ; Khan FM; Powell D; Bayer-Zubek V; Cordon-Cardo C; Costa J; Eastham J; Scardino P
BJU Int; 2012 Jan; 109(1):40-5. PubMed ID: 21771247
[TBL] [Abstract][Full Text] [Related]
10. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Fernandez S; Noldus J; Erbersdobler A; Huland H; Scardino PT; Kattan MW
Urol Oncol; 2002; 7(4):141-6. PubMed ID: 12474529
[TBL] [Abstract][Full Text] [Related]
11. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
13. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
[TBL] [Abstract][Full Text] [Related]
14. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of D'Amico criteria for low-risk prostate cancer.
Milonas D; Kinčius M; Skulčius G; Matjošaitis AJ; GudinavičienĖ I; Jievaltas M
Scand J Urol; 2014 Aug; 48(4):344-9. PubMed ID: 24521187
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the American Joint Committee on Cancer 7th edition staging for localised prostate cancer in Asia treated with external beam radiotherapy.
Wong M; Yip C; Li H; Tan T; Kanesvaran R; Chowbay B; Tan PH; Tan MH; Wong FY
Ann Acad Med Singap; 2014 Oct; 43(10):484-91. PubMed ID: 25434618
[TBL] [Abstract][Full Text] [Related]
17. Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer.
Jereczek-Fossa BA; Maucieri A; Marvaso G; Gandini S; Fodor C; Zerini D; Riva G; Alessandro O; Surgo A; Volpe S; Fanetti G; Arculeo S; Zerella MA; Parisi S; Maisonneuve P; Vavassori A; Cattani F; Cambria R; Garibaldi C; Starzyńska A; Musi G; De Cobelli O; Ferro M; Nolè F; Ciardo D; Orecchia R
Med Oncol; 2018 Nov; 36(1):9. PubMed ID: 30483899
[TBL] [Abstract][Full Text] [Related]
18. Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease.
Zimmermann JS; Osieka R; Bruns T; Hollberg H; Wiechmann B; Netzbandt O; Sablotny J; Malade M; Heitz M; Bernhardt F; Tiemann J; Wilkens M; Brüske T; Welker U; Heinemann V; Zimmermann P; de la Maza SF; Pfeiffer D; Tauber PR; Thomas D; Moustakis C
J Contemp Brachytherapy; 2018 Aug; 10(4):297-305. PubMed ID: 30237813
[TBL] [Abstract][Full Text] [Related]
19. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
